Management of chronic depressive patients with residual symptoms

CNS Drugs

Volumn 27, Issue SUPPL.1, 2013, Pages

  Han, Changsu ^a   Yeh, Tzung Lieh ^b   Kato, Masaki ^c   Sato, Soichiro ^d   Chang, Chia Ming ^e   Pae, Chi Un ^f,g  

^a Korea University College of Medicine   (South Korea)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d Zikei Hospital   (Japan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

^f The Catholic University of Korea   (South Korea)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT;

ANXIETY; CHRONICITY; CLINICAL PRACTICE; DECISION MAKING; DEPRESSION; DISEASE COURSE; DSM-IV-TR; GENDER; HUMAN; MAJOR DEPRESSION; MENTAL PATIENT; PHYSICIAN; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; CHRONIC DISEASE; DRUG COMBINATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84886310643     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0034-x     Document Type: Review

References (32)

1. Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008;9(2):102-14.
2. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR&z.ast;D report. Psychol Med. 2009;22:1-10.
3. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ III, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-5.
4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR&z.ast;D report. Am J Psychiatry. 2006;163(11):1905-17.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
6. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88(Suppl. 2):S61-71.
7. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR&z.ast;D) study. Psychiatr Clin North Am. 2003;26(2):457-94; x.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-96.
9. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol. 2006;16(8):601-11.
10. Beck ATSR, Brown GK. BDI-II beck depression inventory, 2nd edn manual. San Antonia: The Psychological Corporation; 1996.
11. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1(3):385-401.
12. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9): 606-13.
13. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull. 1988;24(4):709-11.
14. Mitchell AJ, Bird V, Rizzo M, Meader N. Diagnostic validity and added value of the Geriatric Depression Scale for depression in primary care: a meta-analysis of GDS30 and GDS15. J Affect Disord. 2010;125(1-3):10-7.
15. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol. 2000;183(3):759-69.
16. Han C, Jo SA, Kwak JH, Pae CU, Steffens D, Jo I, et al. Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric Study. Compr Psychiatry. 2008;49(2):218-23.
17. Han C, Pae CU, Patkar AA, Masand PS, Kim KW, Joe SH, et al. Psychometric properties of the Patient Health Questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients. Psychosomatics. 2009;50(6):580-5.
18. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.
19. Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130(1-2):171-9.
20. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-53.
21. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64(4): 413-20.
22. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry. 2005;17(3):161-5.
23. Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, et al. Long-term safety and tolerability of openlabel aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7: 303-12.
24. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2): 109-27.
25. Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf. 2009;8(3):373-86.
26. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-6.
27. Rush AJ, Wisniewski SR, Zisook S, Fava M, Sung SC, Haley CL, et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR&z.ast;D report. Psychol Med. 2012;42(6):1131-49.
28. Nierenberg A, Trivedi M, Gaynes B, Mitchell J, Davis L, Husain M, et al. Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Aust N Z J Psychiatry. 2009;43:956-67.
29. Thase ME, Trivedi MH, Nelson JC, Fava M, Swanink R, Tran QV, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry. 2008;10(6):440-7.
30. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-53.
31. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
32. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-65.